Bristol to divest Celgene’s psoriasis treatment in FTC clearance push

Bristol announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology and cardiovascular drugs in the largest pharmaceutical industry merger ever.

Original source: https://health.economictimes.indiatimes.com/news/pharma/bristol-to-divest-celgenes-psoriasis-treatment-in-ftc-clearance-push/69928278?utm_source=RSS&utm_medium=ETRSS

Related Posts